个人中心 - 老虎社区

Awkwardly

IP属地：未知

帖子 · 93帖子 · 93
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- AwkwardlyAwkwardly
  ·2021-12-22
  Woah
  Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data
  Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s
  Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data
  2,470 评论
  3
  分享
  举报
- AwkwardlyAwkwardly
  ·2021-10-28
  $ASML Holding NV(ASML)$buy or no
  2,275 1
  点赞
  分享
  举报
- AwkwardlyAwkwardly
  ·2021-10-28
  $Rocket Companies(RKT)$💸💸💸
  1,337 评论
  1
  分享
  举报
- AwkwardlyAwkwardly
  ·2021-10-20
  Wonderful news!
  ASML reports €5.2 billion net sales and €1.7 billion net income in Q3 2021
  Today, ASML Holding NV (ASML) has published its 2021 third-quarter results. Q3 net sales of €5.2 bi
  ASML reports €5.2 billion net sales and €1.7 billion net income in Q3 2021
  2,240 评论
  3
  分享
  举报
- AwkwardlyAwkwardly
  ·2021-09-01
  Tesla is the way to go
  非常抱歉，此主贴已删除
  1,995 评论
  3
  分享
  举报
- AwkwardlyAwkwardly
  ·2021-08-24
  Got to be patient with this
  2,165 评论
  点赞
  分享
  举报
- AwkwardlyAwkwardly
  ·2021-08-19
  $Nokia Oyj(NOK)$to add or to cut?
  2,079 评论
  点赞
  分享
  举报
- AwkwardlyAwkwardly
  ·2021-08-19
  Any thoughts to share from anyone? Korean e commerce player. Huge addressable market!
  637 评论
  点赞
  分享
  举报
- AwkwardlyAwkwardly
  ·2021-08-18
  $Alibaba(BABA)$🤕
  2,759 3
  3
  分享
  举报
- AwkwardlyAwkwardly
  ·2021-08-17
  $Nokia Oyj(NOK)$up or down
  1,943 评论
  点赞
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3581560640770838","uuid":"3581560640770838","gmtCreate":1618468504541,"gmtModify":1746497750430,"name":"Awkwardly","pinyin":"awkwardly","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/ef837769f4e865d22799a099135c74d5","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":8,"headSize":266,"tweetSize":93,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.23","exceedPercentage":"93.41%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.89%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":691680894,"gmtCreate":1640183507241,"gmtModify":1640183738191,"author":{"id":"3581560640770838","authorId":"3581560640770838","name":"Awkwardly","avatar":"https://static.tigerbbs.com/ef837769f4e865d22799a099135c74d5","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581560640770838","authorIdStr":"3581560640770838"},"themes":[],"htmlText":"Woah","listText":"Woah","text":"Woah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691680894","repostId":"1163953446","repostType":4,"repost":{"id":"1163953446","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640182473,"share":"https://www.laohu8.com/m/news/1163953446?lang=&edition=full","pubTime":"2021-12-22 22:14","market":"us","language":"en","title":"Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data","url":"https://stock-news.laohu8.com/highlight/detail?id=1163953446","media":"Tiger Newspress","summary":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s","content":"<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALLK":"Allakos Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163953446","content_text":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.\n\nThe studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.\nIn ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).\nOn the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.\nFollowing this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.\nWilliam Blair downgraded the stock to Market Perform from Outperform.\nAnalysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"\nWith lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.\nCowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.\nSVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.\nBarclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.\nMorgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.\nJefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.\nLifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.","news_type":1,"symbols_score_info":{"ALLK":0.9}},"isVote":1,"tweetType":1,"viewCount":2470,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854369947,"gmtCreate":1635420323334,"gmtModify":1635420323532,"author":{"id":"3581560640770838","authorId":"3581560640770838","name":"Awkwardly","avatar":"https://static.tigerbbs.com/ef837769f4e865d22799a099135c74d5","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581560640770838","authorIdStr":"3581560640770838"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>buy or no","listText":"<a href=\"https://laohu8.com/S/ASML\">$ASML Holding NV(ASML)$</a>buy or no","text":"$ASML Holding NV(ASML)$buy or no","images":[{"img":"https://static.tigerbbs.com/542176b463759c9e49eb2fa5705599b2","width":"1080","height":"3202"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854369947","isVote":1,"tweetType":1,"viewCount":2275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":854360657,"gmtCreate":1635420298875,"gmtModify":1635420298875,"author":{"id":"3581560640770838","authorId":"3581560640770838","name":"Awkwardly","avatar":"https://static.tigerbbs.com/ef837769f4e865d22799a099135c74d5","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581560640770838","authorIdStr":"3581560640770838"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RKT\">$Rocket Companies(RKT)$</a>💸💸💸","listText":"<a href=\"https://laohu8.com/S/RKT\">$Rocket Companies(RKT)$</a>💸💸💸","text":"$Rocket Companies(RKT)$💸💸💸","images":[{"img":"https://static.tigerbbs.com/f4248fe3e8e58293d20c43355574b9d0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854360657","isVote":1,"tweetType":1,"viewCount":1337,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":859539794,"gmtCreate":1634708672183,"gmtModify":1634708835537,"author":{"id":"3581560640770838","authorId":"3581560640770838","name":"Awkwardly","avatar":"https://static.tigerbbs.com/ef837769f4e865d22799a099135c74d5","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581560640770838","authorIdStr":"3581560640770838"},"themes":[],"htmlText":"Wonderful news!","listText":"Wonderful news!","text":"Wonderful news!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859539794","repostId":"1189303892","repostType":4,"repost":{"id":"1189303892","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634706596,"share":"https://www.laohu8.com/m/news/1189303892?lang=&edition=full","pubTime":"2021-10-20 13:09","market":"us","language":"en","title":"ASML reports €5.2 billion net sales and €1.7 billion net income in Q3 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1189303892","media":"Tiger Newspress","summary":"Today, ASML Holding NV (ASML) has published its 2021 third-quarter results.\n\nQ3 net sales of €5.2 bi","content":"<p>Today, ASML Holding NV (ASML) has published its 2021 third-quarter results.</p>\n<ul>\n <li><p>Q3 net sales of €5.2 billion, gross margin of 51.7%, net income of €1.7 billion</p></li>\n <li><p>Q3 net bookings of €6.2 billion</p></li>\n <li><p>ASML expects Q4 2021 net sales between €4.9 billion and €5.2 billion and a gross margin between 51% and 52%</p></li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/efb20490860f1e0c5687de4f41a6c456\" tg-width=\"1142\" tg-height=\"773\" referrerpolicy=\"no-referrer\"></p>\n<p><b>CEO statement and outlook</b></p>\n<p>\"Our third-quarter net sales came in at €5.2 billion with a gross margin of 51.7%, both within our guidance. Our third-quarter net bookings came in at €6.2 billion, including €2.9 billion from EUV systems.</p>\n<p>\"The demand continues to be high. The ongoing digital transformation and current chip shortage fuel the need to increase our capacity to meet the current and expected future demand for Memory and for all Logic nodes.</p>\n<p>\"ASML expects fourth-quarter net sales between €4.9 billion and €5.2 billion with a gross margin between 51% and 52%. ASML expects R&amp;D costs of around €670 million and SG&amp;A costs of around €195 million. For the full year, we are on track to achieving growth approaching 35%,\" said ASML President and Chief Executive Officer Peter Wennink.</p>\n<p><b>Products and business highlights</b></p>\n<ul>\n <li>In theirs EUV business, they had a record quarter in terms of shipments and revenue, due to the volume as well as the share of TWINSCAN NXE:3600D systems.</li>\n <li>The TWINSCAN NXE:3600D achieved a record of 160 wafers per hour at customers' sites.</li>\n <li>In theirs DUV business, they reached a milestone as they shipped the 1000th ArF immersion scanner. The first immersion system designed to support volume manufacturing, the XT:1700Fi, was shipped 15 years ago, in 2006.</li>\n <li>On October 19, 2021, they&nbsp;reached an agreement with Jenoptik AG&nbsp;whereby they will acquire the Medical Applications and Swiss Optic business of Berliner Glas. The deal is targeted to close by the end of the year, subject to regulatory approvals. This concludes our divestment plans regarding the non-semiconductor businesses of Berliner Glas. ASML acquired Berliner Glas in 2020.</li>\n</ul>\n<p><b>Interim dividend and share buyback program update</b></p>\n<p>The interim dividend for 2021 will be €1.80 per ordinary share. The ex-dividend date as well as the fixing date for the EUR/USD conversion will be November 2, 2021, and the record date will be November 3, 2021. The dividend will be made payable on November 12, 2021.</p>\n<p>As part of its financial policy to return excess cash to its shareholders through growing annualized dividends and regularly timed share buybacks, ASML announced a new share buyback program which started on July 22, 2021, and is to be executed by December 31, 2023. As part of this program, ASML intends to repurchase shares up to an amount of €9 billion, of which we expect a total of up to 0.45 million shares will be used to cover employee share plans. ASML intends to cancel the remainder of the shares repurchased. In the third quarter, they purchased around €2.4 billion of shares under the current and previous program.</p>\n<p>The share buyback program will be executed within the limitations of the existing authority granted by the Annual General Meeting of Shareholders (AGM) on April 29, 2021, and of the authority to be granted by future AGMs. The share buyback program may be suspended, modified or discontinued at any time.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASML reports €5.2 billion net sales and €1.7 billion net income in Q3 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASML reports €5.2 billion net sales and €1.7 billion net income in Q3 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-20 13:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Today, ASML Holding NV (ASML) has published its 2021 third-quarter results.</p>\n<ul>\n <li><p>Q3 net sales of €5.2 billion, gross margin of 51.7%, net income of €1.7 billion</p></li>\n <li><p>Q3 net bookings of €6.2 billion</p></li>\n <li><p>ASML expects Q4 2021 net sales between €4.9 billion and €5.2 billion and a gross margin between 51% and 52%</p></li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/efb20490860f1e0c5687de4f41a6c456\" tg-width=\"1142\" tg-height=\"773\" referrerpolicy=\"no-referrer\"></p>\n<p><b>CEO statement and outlook</b></p>\n<p>\"Our third-quarter net sales came in at €5.2 billion with a gross margin of 51.7%, both within our guidance. Our third-quarter net bookings came in at €6.2 billion, including €2.9 billion from EUV systems.</p>\n<p>\"The demand continues to be high. The ongoing digital transformation and current chip shortage fuel the need to increase our capacity to meet the current and expected future demand for Memory and for all Logic nodes.</p>\n<p>\"ASML expects fourth-quarter net sales between €4.9 billion and €5.2 billion with a gross margin between 51% and 52%. ASML expects R&amp;D costs of around €670 million and SG&amp;A costs of around €195 million. For the full year, we are on track to achieving growth approaching 35%,\" said ASML President and Chief Executive Officer Peter Wennink.</p>\n<p><b>Products and business highlights</b></p>\n<ul>\n <li>In theirs EUV business, they had a record quarter in terms of shipments and revenue, due to the volume as well as the share of TWINSCAN NXE:3600D systems.</li>\n <li>The TWINSCAN NXE:3600D achieved a record of 160 wafers per hour at customers' sites.</li>\n <li>In theirs DUV business, they reached a milestone as they shipped the 1000th ArF immersion scanner. The first immersion system designed to support volume manufacturing, the XT:1700Fi, was shipped 15 years ago, in 2006.</li>\n <li>On October 19, 2021, they&nbsp;reached an agreement with Jenoptik AG&nbsp;whereby they will acquire the Medical Applications and Swiss Optic business of Berliner Glas. The deal is targeted to close by the end of the year, subject to regulatory approvals. This concludes our divestment plans regarding the non-semiconductor businesses of Berliner Glas. ASML acquired Berliner Glas in 2020.</li>\n</ul>\n<p><b>Interim dividend and share buyback program update</b></p>\n<p>The interim dividend for 2021 will be €1.80 per ordinary share. The ex-dividend date as well as the fixing date for the EUR/USD conversion will be November 2, 2021, and the record date will be November 3, 2021. The dividend will be made payable on November 12, 2021.</p>\n<p>As part of its financial policy to return excess cash to its shareholders through growing annualized dividends and regularly timed share buybacks, ASML announced a new share buyback program which started on July 22, 2021, and is to be executed by December 31, 2023. As part of this program, ASML intends to repurchase shares up to an amount of €9 billion, of which we expect a total of up to 0.45 million shares will be used to cover employee share plans. ASML intends to cancel the remainder of the shares repurchased. In the third quarter, they purchased around €2.4 billion of shares under the current and previous program.</p>\n<p>The share buyback program will be executed within the limitations of the existing authority granted by the Annual General Meeting of Shareholders (AGM) on April 29, 2021, and of the authority to be granted by future AGMs. The share buyback program may be suspended, modified or discontinued at any time.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ASML":"阿斯麦"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189303892","content_text":"Today, ASML Holding NV (ASML) has published its 2021 third-quarter results.\n\nQ3 net sales of €5.2 billion, gross margin of 51.7%, net income of €1.7 billion\nQ3 net bookings of €6.2 billion\nASML expects Q4 2021 net sales between €4.9 billion and €5.2 billion and a gross margin between 51% and 52%\n\n\nCEO statement and outlook\n\"Our third-quarter net sales came in at €5.2 billion with a gross margin of 51.7%, both within our guidance. Our third-quarter net bookings came in at €6.2 billion, including €2.9 billion from EUV systems.\n\"The demand continues to be high. The ongoing digital transformation and current chip shortage fuel the need to increase our capacity to meet the current and expected future demand for Memory and for all Logic nodes.\n\"ASML expects fourth-quarter net sales between €4.9 billion and €5.2 billion with a gross margin between 51% and 52%. ASML expects R&D costs of around €670 million and SG&A costs of around €195 million. For the full year, we are on track to achieving growth approaching 35%,\" said ASML President and Chief Executive Officer Peter Wennink.\nProducts and business highlights\n\nIn theirs EUV business, they had a record quarter in terms of shipments and revenue, due to the volume as well as the share of TWINSCAN NXE:3600D systems.\nThe TWINSCAN NXE:3600D achieved a record of 160 wafers per hour at customers' sites.\nIn theirs DUV business, they reached a milestone as they shipped the 1000th ArF immersion scanner. The first immersion system designed to support volume manufacturing, the XT:1700Fi, was shipped 15 years ago, in 2006.\nOn October 19, 2021, they reached an agreement with Jenoptik AG whereby they will acquire the Medical Applications and Swiss Optic business of Berliner Glas. The deal is targeted to close by the end of the year, subject to regulatory approvals. This concludes our divestment plans regarding the non-semiconductor businesses of Berliner Glas. ASML acquired Berliner Glas in 2020.\n\nInterim dividend and share buyback program update\nThe interim dividend for 2021 will be €1.80 per ordinary share. The ex-dividend date as well as the fixing date for the EUR/USD conversion will be November 2, 2021, and the record date will be November 3, 2021. The dividend will be made payable on November 12, 2021.\nAs part of its financial policy to return excess cash to its shareholders through growing annualized dividends and regularly timed share buybacks, ASML announced a new share buyback program which started on July 22, 2021, and is to be executed by December 31, 2023. As part of this program, ASML intends to repurchase shares up to an amount of €9 billion, of which we expect a total of up to 0.45 million shares will be used to cover employee share plans. ASML intends to cancel the remainder of the shares repurchased. In the third quarter, they purchased around €2.4 billion of shares under the current and previous program.\nThe share buyback program will be executed within the limitations of the existing authority granted by the Annual General Meeting of Shareholders (AGM) on April 29, 2021, and of the authority to be granted by future AGMs. The share buyback program may be suspended, modified or discontinued at any time.","news_type":1,"symbols_score_info":{"ASML":0.9}},"isVote":1,"tweetType":1,"viewCount":2240,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":816686908,"gmtCreate":1630496379704,"gmtModify":1631888258655,"author":{"id":"3581560640770838","authorId":"3581560640770838","name":"Awkwardly","avatar":"https://static.tigerbbs.com/ef837769f4e865d22799a099135c74d5","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581560640770838","authorIdStr":"3581560640770838"},"themes":[],"htmlText":"Tesla is the way to go","listText":"Tesla is the way to go","text":"Tesla is the way to go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/816686908","repostId":"1123085822","repostType":4,"isVote":1,"tweetType":1,"viewCount":1995,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834077184,"gmtCreate":1629764732648,"gmtModify":1631888258670,"author":{"id":"3581560640770838","authorId":"3581560640770838","name":"Awkwardly","avatar":"https://static.tigerbbs.com/ef837769f4e865d22799a099135c74d5","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581560640770838","authorIdStr":"3581560640770838"},"themes":[],"htmlText":"Got to be patient with this","listText":"Got to be patient with this","text":"Got to be patient with this","images":[{"img":"https://static.tigerbbs.com/1843f483daef024b672e374947af0586","width":"1080","height":"2126"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/834077184","isVote":1,"tweetType":1,"viewCount":2165,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":831759218,"gmtCreate":1629352061234,"gmtModify":1631886967873,"author":{"id":"3581560640770838","authorId":"3581560640770838","name":"Awkwardly","avatar":"https://static.tigerbbs.com/ef837769f4e865d22799a099135c74d5","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581560640770838","authorIdStr":"3581560640770838"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NOK\">$Nokia Oyj(NOK)$</a>to add or to cut?","listText":"<a href=\"https://laohu8.com/S/NOK\">$Nokia Oyj(NOK)$</a>to add or to cut?","text":"$Nokia Oyj(NOK)$to add or to cut?","images":[{"img":"https://static.tigerbbs.com/c3667ef19a4cadfed3bafbf6eb1c7ace","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/831759218","isVote":1,"tweetType":1,"viewCount":2079,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":831759081,"gmtCreate":1629351999843,"gmtModify":1631888258682,"author":{"id":"3581560640770838","authorId":"3581560640770838","name":"Awkwardly","avatar":"https://static.tigerbbs.com/ef837769f4e865d22799a099135c74d5","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581560640770838","authorIdStr":"3581560640770838"},"themes":[],"htmlText":"Any thoughts to share from anyone? Korean e commerce player. Huge addressable market!","listText":"Any thoughts to share from anyone? Korean e commerce player. Huge addressable market!","text":"Any thoughts to share from anyone? Korean e commerce player. Huge addressable market!","images":[{"img":"https://static.tigerbbs.com/c4f71ec0f00c60c628f67b4183c39148","width":"1080","height":"3100"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/831759081","isVote":1,"tweetType":1,"viewCount":637,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":831867851,"gmtCreate":1629301413973,"gmtModify":1631888258700,"author":{"id":"3581560640770838","authorId":"3581560640770838","name":"Awkwardly","avatar":"https://static.tigerbbs.com/ef837769f4e865d22799a099135c74d5","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581560640770838","authorIdStr":"3581560640770838"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>🤕","listText":"<a href=\"https://laohu8.com/S/BABA\">$Alibaba(BABA)$</a>🤕","text":"$Alibaba(BABA)$🤕","images":[{"img":"https://static.tigerbbs.com/d7ab346697f6e8344cf82d5d19c95f86","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/831867851","isVote":1,"tweetType":1,"viewCount":2759,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":839804630,"gmtCreate":1629131872120,"gmtModify":1631886967900,"author":{"id":"3581560640770838","authorId":"3581560640770838","name":"Awkwardly","avatar":"https://static.tigerbbs.com/ef837769f4e865d22799a099135c74d5","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581560640770838","authorIdStr":"3581560640770838"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NOK\">$Nokia Oyj(NOK)$</a>up or down","listText":"<a href=\"https://laohu8.com/S/NOK\">$Nokia Oyj(NOK)$</a>up or down","text":"$Nokia Oyj(NOK)$up or down","images":[{"img":"https://static.tigerbbs.com/7c317df536ddfb38e767ee974ecad9f4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/839804630","isVote":1,"tweetType":1,"viewCount":1943,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}